Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : BLUE save search
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
Published: 2023-12-08 (Crawled : 22:00) - biospace.com/
BLUE | $0.9729 2.09% 6.5M
|
Health Technology
|
| O: 6.03%
H: 8.43%
C: -43.92%
fda disease approval cell
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
Published: 2023-08-16 (Crawled : 13:00) - biospace.com/
BLUE | $0.9729 2.09% 6.5M
|
Health Technology
|
| O: -1.66%
H: 2.81%
C: 0.28%
fda disease cell meeting therapy
bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
Published: 2023-06-21 (Crawled : 12:00) - biospace.com/
BLUE | $0.9729 2.09% 6.5M
|
Health Technology
|
| O: 0.85%
H: 1.13%
C: -3.39%
fda disease license review cell application
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
Published: 2023-04-24 (Crawled : 12:00) - biospace.com/
BLUE | $0.9729 2.09% 6.5M
|
Health Technology
|
| O: 9.04%
H: 0.27%
C: -8.02%
fda disease license cell application
FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
Published: 2022-12-19 (Crawled : 13:00) - biospace.com/
BLUE | $0.9729 2.09% 6.5M
|
Health Technology
|
| O: 0.0%
H: 1.23%
C: -6.75%
fda disease clinical hold
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2022-08-17 (Crawled : 22:00) - biospace.com/
BLUE | $0.9729 2.09% 6.5M
|
Health Technology
|
| O: -4.41%
H: 30.05%
C: 7.79%
zynteglo fda blood approval therapy
FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions
Published: 2022-08-17 (Crawled : 18:00) - prnewswire.com
BLUE | $0.9729 2.09% 6.5M
|
Health Technology
|
| O: -4.41%
H: 30.05%
C: 7.79%
fda blood therapy
FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2022-06-10 (Crawled : 22:00) - biospace.com/
BLUE | $0.9729 2.09% 6.5M
|
Health Technology
| Email alert
Add to watchlist
fda blood therapy
bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting
Published: 2022-06-07 (Crawled : 13:20) - biospace.com/
BLUE | $0.9729 2.09% 6.5M
|
Health Technology
|
| O: -1.01%
H: 22.68%
C: 22.37%
fda
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)
Published: 2022-01-18 (Crawled : 12:30) - biospace.com/
BLUE | $0.9729 2.09% 6.5M
|
Health Technology
|
| O: -3.19%
H: 1.0%
C: -6.94%
fda cel
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2021-11-22 (Crawled : 14:30) - biospace.com/
BLUE | $0.9729 2.09% 6.5M
|
Health Technology
|
| O: 5.7%
H: 0.44%
C: -6.81%
fda blood transfusion application gene therapy therapy license cel
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2021-09-21 (Crawled : 01:00) - biospace.com/
BLUE | $0.9729 2.09% 6.5M
|
Health Technology
|
| O: 0.0%
H: 1.56%
C: 0.11%
fda blood gene therapy therapy license gene therapies cel
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
Published: 2021-06-07 (Crawled : 13:00) - biospace.com/
BLUE | $0.9729 2.09% 6.5M
|
Health Technology
|
| O: 4.85%
H: 0.46%
C: -1.36%
disease fda clinical hold
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.